EP1871347
Lyfjasamsetning
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
18.4.2006EP published:
3.8.2016EP application number:
06750475.3
EP translation filed:
24.10.2016Grant published:
15.11.2016EPO information:
European Patent Register
Max expiry date:
17.4.2026Expiry date:
17.4.2021
Title:
PHARMACEUTICAL COMPOSITION
Timeline
Today
18.4.2006EP application
3.8.2016EP Publication
24.10.2016Translation submitted
15.11.2016Registration published
17.4.2021Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
CARTER, Barry Howard,GlaxoSmithKline Corp. Int.Address:
North Carolina, US
Name:
CAMPBELL, Dwayne A.,GlaxoSmithKline Corp. Int.Address:
North Carolina, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
672805 PDate:
19.4.2005Country:
US
Classification
Categories:
A61K 9/20, A61K 31/517, A61K 9/28, C07D 405/04
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 24.3.2017
Expires: 17.4.2018
Payer: Árnason Faktor
Number: 13
Paid: 27.3.2018
Expires: 17.4.2019
Payer: Árnason Faktor
Number: 14
Paid: 26.3.2019
Expires: 17.4.2020
Payer: Árnason Faktor
Number: 15
Paid: 26.3.2020
Expires: 17.4.2021
Payer: Árnason Faktor ehf.